On the barrier properties of the cornea: a microscopy study of the penetration of fluorescently labeled nanoparticles, polymers, and sodium fluorescein

Article English OPEN
Mun, Ellina A. ; Morrison, Peter W. J. ; Williams, Adrian C. ; Khutoryanskiy, Vitaliy V. (2014)
  • Publisher: American Chemical Society
  • Related identifiers: doi: 10.1021/mp500332m
  • Subject: RM
    mesheuropmc: eye diseases | sense organs

Overcoming the natural defensive barrier functions of the eye remains one of the greatest challenges of ocular drug delivery. Cornea is a chemical and mechanical barrier preventing the passage of any foreign bodies including drugs into the eye, but the factors limiting penetration of permeants and nanoparticulate drug delivery systems through the cornea are still not fully understood. In this study, we investigate these barrier properties of the cornea using thiolated and PEGylated (750 and 5000 Da) nanoparticles, sodium fluorescein, and two linear polymers (dextran and polyethylene glycol). Experiments used intact bovine cornea in addition to bovine cornea de-epithelialized or tissues pretreated with cyclodextrin. It was shown that corneal epithelium is the major barrier for permeation; pretreatment of the cornea with β-cyclodextrin provides higher permeation of low molecular weight compounds, such as sodium fluorescein, but does not enhance penetration of nanoparticles and larger molecules. Studying penetration of thiolated and PEGylated (750 and 5000 Da) nanoparticles into the de-epithelialized ocular tissue revealed that interactions between corneal surface and thiol groups of nanoparticles were more significant determinants of penetration than particle size (for the sizes used here). PEGylation with polyethylene glycol of a higher molecular weight (5000 Da) allows penetration of nanoparticles into the stroma, which proceeds gradually, after an initial 1 h lag phase.
  • References (71)
    71 references, page 1 of 8

    (1) Yorio, T.; Clark, A. F.; Wax, M. B. Ocular Therapeutics; Eye on New Discoveries; Elsevier: 2008; pp 3−30.

    (2) World Health Organization [http://www.who.int/blindness/ history/en/].

    (3) Hornof, M.; Toropainen, E.; Uttri, A. Cell culture models of the ocular barriers. Eur. J. Pharm. Biopharm. 2005, 60, 207−225.

    (4) Ranta, V. P.; Urtti, A. Transscleral drug delivery to the posterior eye: Prospects of pharmacokinetic modeling. Adv. Drug Delivery Rev.

    (5) (a) Laude, A.; Tan, L. E.; Wilson, C. G.; Lascaratos, G.; Elashry, M.; Aslam, T.; Patton, N.; Dhillon, B. Intravitreal therapy for neovascular age-related macular degeneration and inter-individual variations in vitreous pharmacokinetics. Prog. Retinal Eye Res. 2010, 29, 466−475. (b) Wilson, C. G. Topical drug delivery in the eye. Exp. Eye Res. 2004, 78, 737−743. (c) Hughes, P. M.; Olejnik, O.; Chang-Lin, J.- E.; Wilson, C. G. Topical and systemic drug delivery to the posterior segments. Adv. Drug Delivery Rev. 2005, 57, 2010−2032.

    (6) Bochot, A.; Fattal, E. Liposomes for intravitreal drug delivery: A state of the art. J. Controlled Release 2012, 161, 628−634.

    (7) Thrimawithana, T. R.; Young, S.; Bunt, C. R.; Green, C.; Alany, R. G. Drug delivery to the posterior segment of the eye. Drug Discovery Today 2011, 16, 270−277.

    (8) Geroski, D. H.; Edelhauser, H. F. Drug delivery for posterior segment eye disease. Invest. Ophthalmol. Visual Sci. 2000, 41, 961−964.

    (9) Urtti, A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv. Drug Delivery Rev. 2006, 58, 1131−1135.

    (10) Jarvinen, K.; Jarvinen, T.; Urtti, A. Ocular absorption following topical delivery. Adv. Drug Delivery Rev. 1995, 16, 3−19.

  • Related Research Results (1)
  • Metrics
    No metrics available
Share - Bookmark